KeyMed Biosciences Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
1,768
- Stock Symbol
-
02162
- Investments
-
3
- Share Price
-
$8.90
- (As of Friday Closing)
KeyMed Biosciences General Information
Description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact Information
Website
www.keymedbio.comCorporate Office
- Building D2, Chengdu Tianfu International Bio-town
- Shuangliu District
- Chengdu, Sichuan
- China
Corporate Office
- Building D2, Chengdu Tianfu International Bio-town
- Shuangliu District
- Chengdu, Sichuan
- China
KeyMed Biosciences Stock Performance
As of 13-Nov-2026, KeyMed Biosciences’s stock price is $8.90. Its current market cap is $2.62B with 295M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.90 | $9.05 | $5.72 - $11.44 | $2.62B | 295M | 2.18M | $0.38 |
KeyMed Biosciences Financials Summary
As of 30-Jun-2026, KeyMed Biosciences has a trailing 12-month revenue of $119M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,497,307 | 1,739,851 | 854,872 | 1,372,903 |
| Revenue | 119,278 | 99,608 | 59,665 | 50,050 |
| EBITDA | 159,646 | (66,187) | (67,632) | (50,618) |
| Net Income | 110,563 | (72,677) | (71,806) | (50,793) |
| Total Assets | 834,455 | 602,789 | 515,961 | 547,770 |
| Total Debt | 102,541 | 112,702 | 103,182 | 59,068 |
KeyMed Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
KeyMed Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
KeyMed Biosciences Signals
KeyMed Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
KeyMed Biosciences Investments (3)
KeyMed Biosciences’s most recent deal was a Secondary Transaction - Private with Chengdu Kangnuoxing for . The deal was made on 26-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Chengdu Kangnuoxing | 26-Jun-2023 | Secondary Transaction - Private | Biotechnology | ||
| Tiannuojiancheng Pharma (InnoCare Pharma / Keymed Biosciences) | 17-Sep-2021 | Joint Venture | Drug Discovery | ||
| KYM Biosciences | 02-Dec-2019 | Joint Venture | Drug Discovery |
KeyMed Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.14 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
KeyMed Biosciences Exits (1)
KeyMed Biosciences’s most recent exit was on 26-Jun-2023 from Chengdu Kangnuoxing. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Chengdu Kangnuoxing | 26-Jun-2023 | Completed |
|
KeyMed Biosciences FAQs
-
When was KeyMed Biosciences founded?
KeyMed Biosciences was founded in 2016.
-
Where is KeyMed Biosciences headquartered?
KeyMed Biosciences is headquartered in Chengdu, China.
-
What is the size of KeyMed Biosciences?
KeyMed Biosciences has 1,768 total employees.
-
What industry is KeyMed Biosciences in?
KeyMed Biosciences’s primary industry is Drug Discovery.
-
Is KeyMed Biosciences a private or public company?
KeyMed Biosciences is a Public company.
-
What is KeyMed Biosciences’s stock symbol?
The ticker symbol for KeyMed Biosciences is 02162.
-
What is the current stock price of KeyMed Biosciences?
As of 13-Nov-2026 the stock price of KeyMed Biosciences is $8.90.
-
What is the current market cap of KeyMed Biosciences?
The current market capitalization of KeyMed Biosciences is $2.62B.
-
What is KeyMed Biosciences’s current revenue?
The trailing twelve month revenue for KeyMed Biosciences is $119M.
-
What is KeyMed Biosciences’s annual earnings per share (EPS)?
KeyMed Biosciences’s EPS for 12 months was $0.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process